AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Global Viral Vector & Plasmid DNA Manufacturing Market Analysis Report 2019-2025 - ResearchAndMarkets.com

February 21, 2019

DUBLIN--(BUSINESS WIRE)--Feb 21, 2019--The “Viral Vector & Plasmid DNA Manufacturing Market Analysis Report By Application, By Disease (Cancer, Genetic), By Workflow (Upstream, Downstream), By Vector, By End Use, And Segment Forecasts, 2019 - 2025” report has been added to ResearchAndMarkets.com’s offering.

The global viral vector & plasmid DNA manufacturing market size is expected to reach USD 882.9 million by 2025, rising at a 16.0% CAGR during the forecast period.

Rising number of gene therapy-based discovery programs in the pharma industry is one of the key trends driving the production of gene therapy vectors. Moreover, a robust pipeline of viral vaccines and gene therapies has prompted companies to develop novel and effective technologies for scalable manufacturing of vectors. Current vector manufacturing process is considered highly regulated, elaborate, and expensive.

Moreover, at present, there is a shortage of production sites to meet the demand by the pharmaceutical industry for vector construction services. These factors have created opportunities for companies to capitalize on potential avenues in the market through developing novel solutions.

Key growth strategies adopted by companies to sustain their market presence include continuous expansion of manufacturing sites in high-demand markets such as the U.S. and U.K. Moreover, companies are engaged in strategic mergers & facility acquisitions to meet growing requirements of viral vectors within the pharmaceutical and biotech industries and to broaden their service portfolios.

Further Key Findings From the Report Suggest:

Key Topics Covered:

Chapter 1 Executive Summary

1.1 Market Snapshot

Chapter 2 Research Methodology

2.1 Information Procurement 2.2 Data Analysis 2.3 Market Formulation & Validation 2.4 Approaches for Market Estimation

Chapter 3 Viral Vector & Plasmid DNA Manufacturing Market Variables, Trends & Scope

3.1 Market Segmentation & Scope 3.1.1 Market driver analysis 3.1.1.1 Robust pipeline for gene therapies and viral vector vaccines 3.1.1.2 Technological advancements for vector production 3.1.1.3 Highly competitive market and various marketing strategies undertaken by the operating entities 3.1.2 Market restraint analysis 3.1.2.1 Regulatory, scientific, and ethical challenges associated with gene therapy 3.1.3 Challenge analysis 3.1.3.1 Production capacity challenges 3.1.3.2 Manufacturing challenges pertaining to the production of vector at large scale 3.1.4 Opportunity analysis 3.1.4.1 Facility expansion for cell and gene therapies 3.1.4.2 Investments, collaboration & partnerships in cell and gene therapies space 3.2 Penetration & Growth Prospect Mapping For Vector Type, 2017 3.3 Viral Vector & Plasmid DNA Manufacturing Market-Swot Analysis, By Factor (Political & Legal, Economic And Technological) 3.4 Industry Analysis - Porter’s

Chapter 4 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Vector Type Estimates & Trend Analysis

4.1 Viral Vector & Plasmid DNA Manufacturing Market: Vector Type Movement Analysis 4.2 Adenovirus 4.3 Retrovirus 4.4 Plasmid DNA 4.5 AAV 4.6 Lentivirus 4.7 Other Vectors

Chapter 5 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Workflow Estimates & Trend Analysis

5.1 Viral Vector & Plasmid DNA Manufacturing Market: Workflow Movement Analysis 5.2 Upstream Manufacturing 5.2.2 Vector amplification & expansion 5.2.3 Vector recovery/harvesting 5.3 Downstream Manufacturing 5.3.2 Purification 5.3.3 Fill-finish

Chapter 6 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Application Estimates & Trend Analysis

6.1 Viral Vector & Plasmid DNA Manufacturing Market: Application Movement Analysis 6.2 Antisense, RNAi, & Molecular Therapy 6.3 Vaccinology

Chapter 7 Viral Vector & Plasmid DNA Manufacturing Market Categorization: End-use Estimates & Trend Analysis

7.1 Viral Vector & Plasmid DNA Manufacturing Market: End-use Movement Analysis 7.2 Pharmaceutical and Biopharmaceutical Companies| 7.3 Research Institutes

Chapter 8 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Disease Estimates & Trend Analysis

8.1 Viral Vector & Plasmid DNA Manufacturing Market: Disease Movement Analysis 8.2 Cancer 8.3 Genetic disorders 8.4 Infectious diseases 8.5 Others

Chapter 9 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Regional Estimates & Trend Analysis

9.1 Viral Vector & Plasmid DNA Manufacturing Market Share By Regional, 2017 & 2025 9.2 North America 9.3 Europe 9.4 Asia Pacific 9.5 Latin America 9.6 MEA

Chapter 10 Competitive Landscape

10.1 List of Companies With Portfolio for Vector-based Therapeutic Candidate 10.2 List of Vector Manufacturers 10.3 Strategy Framework 10.4 Market Participation Categorization 10.5 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/dxb9s4/global_viral?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190221005404/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Genomics,Molecular Diagnostics

KEYWORD: EUROPE ASIA PACIFIC NORTH AMERICA

INDUSTRY KEYWORD: HEALTH GENETICS

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/21/2019 05:38 AM/DISC: 02/21/2019 05:38 AM

http://www.businesswire.com/news/home/20190221005404/en